Ipamorelin

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide that belongs to the growth-hormone secretagogue (GHS) family. Rather than supplying growth hormone from outside the body, it signals the pituitary gland to release the growth hormone you already make — mimicking the action of ghrelin, the body's natural hunger-and-GH hormone, at its receptor.

What sets ipamorelin apart is its selectivity. It stimulates growth-hormone release with little to no effect on cortisol, prolactin, or other pituitary hormones — a cleaner profile than earlier secretagogues. It is not an FDA-approved drug; in the United States it is prescribed only as a pharmacy-compounded preparation under physician supervision, frequently alongside the GHRH analog CJC-1295.

How Ipamorelin works

Ipamorelin binds the growth-hormone secretagogue receptor (GHS-R1a) — the same receptor targeted by ghrelin — on cells of the anterior pituitary. This triggers a pulse of growth-hormone release that follows the body's own rhythm rather than flooding the system with a constant supply, which is thought to preserve the natural feedback loop.

Its defining feature is receptor selectivity: at doses that reliably raise growth hormone, ipamorelin produces minimal increases in cortisol and prolactin and does not meaningfully stimulate appetite the way some older GHS compounds do. Because it works on a different pathway than growth-hormone-releasing hormone (GHRH), it is often combined with a GHRH analog such as CJC-1295, where the two mechanisms produce a larger, more physiologic GH pulse together than either does alone.

What Ipamorelin is used for

What the evidence shows

Ipamorelin was first characterized as 'the first selective growth hormone secretagogue,' notable for raising growth hormone without the cortisol and prolactin bumps seen with earlier GHS compounds [1]. Human pharmacokinetic-pharmacodynamic work confirmed a dose-dependent, well-tolerated GH response in healthy volunteers [2].

Beyond those foundational studies, the clinical literature is limited: much of the human data comes from early-phase and specialty settings — for example, a trial evaluating ipamorelin for recovery of gastrointestinal function after bowel surgery — rather than large, long-term trials in healthy adults seeking body-composition or anti-aging benefits [3].

We present this honestly to every patient. Ipamorelin is used in clinical practice on the strength of its selectivity, tolerability, and mechanistic rationale — not on the basis of large efficacy trials for physique or longevity endpoints — and that distinction matters when you are deciding whether it fits your goals.

Dosing & administration context

Ipamorelin is administered by subcutaneous injection, and because growth hormone is released in pulses tied to sleep and fasting, protocols are usually timed to before bed and/or away from meals. Doses are individualized and courses are typically cycled rather than run continuously.

The specific dose, timing, frequency, duration, and any pairing with CJC-1295 are set by the prescribing physician based on your goals, labs, and response — which is why we frame this as clinical context, not a self-dosing guide. Ipamorelin obtained without a prescription (research-only vials, gray-market powders) carries no guarantee of identity, purity, or sterility.

Ipamorelin is not an FDA-approved medication. Content on this page is clinical context for physician-supervised, pharmacy-compounded use — not a dosing guide or a substitute for medical advice.

Safety & side effects

Ipamorelin's selectivity is the core of its safety story: at appropriate doses it raises growth hormone with minimal effect on cortisol and prolactin, and it is generally well tolerated. Reported effects in clinical use are usually mild and self-limiting.

Because it raises growth hormone and, indirectly, IGF-1, we screen carefully before prescribing and monitor throughout a course. The most important safety principle is source control — a pharmacy-compounded product from a licensed 503A/503B pharmacy is a fundamentally different risk profile than a research vial of unknown origin.

How Strong Health prescribes Ipamorelin

At Strong Health, ipamorelin is prescribed only after an in-person or telehealth physician evaluation, a review of your goals and history, and relevant labs — including a baseline IGF-1 where appropriate. It is dispensed exclusively through licensed 503A or 503B compounding pharmacies under physician orders; we do not sell or recommend research-only product.

We treat ipamorelin as one component of a plan, not a standalone fix. It is frequently paired with the GHRH analog CJC-1295 to produce a stronger, more physiologic growth-hormone pulse, and it works best alongside training, nutrition, and sleep. Your physician sets the protocol, rechecks labs and response at scheduled intervals, and adjusts or stops treatment based on how you actually respond.

Available in person at our Miami (Brickell) clinic and via telehealth across our service areas.

Frequently asked questions